Aflac stock holds above $116 as Q2 2026 earnings show modest revenue beat

AFLAC Inc. (US0010551028) stock is trading a little above $116 per share as of the most recent session in August 2026, with investors weighing mixed second-quarter 2026 results and fresh institutional moves in the shares. The latest data show the price fluctuating between $116.62 and $120.14 in recent insider-related transactions in August 2026, underscoring that the current level around $116.83 is close to the higher end of that range.

Q2 2026 earnings mix revenue beat with EPS shortfall

Recent reporting on AFLAC's second-quarter 2026 financials indicates that adjusted earnings per share came in at $1.75 for the quarter, compared with an analyst forecast of $1.78 for the same period, a shortfall of $0.03 per share in EPS. Revenue for Q2 2026 was reported at $4.12 billion, modestly ahead of the anticipated $4.11 billion, meaning the company delivered a $0.01 billion revenue beat against expectations for that reporting period. This combination of a slight earnings miss alongside a small revenue beat paints a nuanced picture of AFLAC's operating performance for the three months ended in June 2026.

Because the Q2 2026 quarter-end falls well within nine months of August 22, 2026, these figures represent the most current set of reported fundamentals for the company. The EPS and revenue outcomes versus expectations are likely to feed into ongoing consensus modeling, with the revenue beat suggesting resilient top-line trends even as bottom-line margin dynamics remain under scrutiny.

Ownership changes and consensus view

In parallel with the earnings narrative, an institutional shareholder with a 10 percent stake in AFLAC recently disposed of 12,700 shares of common stock, a move executed at prices between $116.62 and $120.14 per share during August 2026. The dollar value of those sales reached roughly $1.48 million at prevailing market prices, providing a concrete data point on liquidity and institutional trading interest at current valuations.

Separate portfolio disclosures indicate that specialist investment firms have initiated or expanded AFLAC positions, including new allocations measured in the low- to mid-single-digit millions of dollars in August 2026. These flows contribute to an evolving ownership base at a time when the stock carries a consensus rating classified as Hold with an average price target of $116.62, aligning closely with the observed spot price near $116.83 in late August 2026. The proximity between the average target and the trading level suggests that, on current numbers, the market and consensus views are broadly in equilibrium.

Valuation context for AFLAC stock

With AFLAC shares changing hands in the $116 to $120 band in August 2026, investors can infer a market capitalization in the tens of billions of dollars, given the insurer's large established equity base and its dual exposure to the United States and Japan through its supplemental health and life insurance operations. The modest revenue beat of $4.12 billion versus $4.11 billion in Q2 2026 may help support that valuation by signaling steady demand for core products in key markets, even as the $1.75 adjusted EPS print falling $0.03 short of forecasts prompts closer examination of expense and claims trends.

For comparison, historical data for prior fiscal periods had already shown AFLAC delivering multi-billion-dollar revenues and robust earnings, but those older figures, such as fiscal 2023 outcomes, now serve primarily as a backdrop rather than a current gauge. The Q2 2026 numbers, by contrast, form the live basis for assessing valuation multiples like price-to-earnings and price-to-sales, although exact ratio calculations will depend on updated trailing and forward estimates in investors' own models.

Core insurance offering: supplemental cancer and health cover

AFLAC Inc. is best known for its supplemental insurance products, including its flagship cancer and serious illness policies that provide cash benefits to policyholders facing diagnosis and treatment. These offerings are structured to complement primary health insurance by delivering direct cash payouts that can be used for non-medical expenses such as travel, family support, and lost income, giving customers financial flexibility during medical events.

The product range typically spans cancer insurance, accident coverage, hospital indemnity plans, and short-term disability policies, all of which generate recurring premium income that feeds into the multi-billion-dollar revenue base reflected in the Q2 2026 figure of $4.12 billion. As AFLAC updates and tailors these products to evolving regulatory environments and consumer needs in the United States and Japan, performance in segments like cancer and health cover will remain integral to the company's ability to sustain or grow earnings beyond the $1.75 per share level reported for the latest quarter.

Stock level and investor takeaway

As of the most recent trading session in August 2026, AFLAC stock is trading close to $116.83 per share in USD on its New York Stock Exchange listing, which is very close to the consensus price target of $116.62 and within the recent transaction range of $116.62 to $120.14 that featured in insider-related selling activity of 12,700 shares valued at $1.48 million. This alignment between trading price, recent institutional transactions, and the average target suggests that, based on the latest Q2 2026 revenue of $4.12 billion and adjusted EPS of $1.75 versus a $1.78 forecast, the market is currently pricing AFLAC shares in line with prevailing analyst expectations.

Fact box

Company: AFLAC Inc.

ISIN: US0010551028

Ticker: AFL

Exchange: New York Stock Exchange

Sector / Industry: Financials / Insurance

Index membership: S&P 500